You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

 

Online download statistics by month:

Online download statistics by month: June 2020 to May 2026

AbstractFullPdf
Jun 2020208208105
Jul 202018018068
Aug 2020757330
Sep 2020969636
Oct 2020656536
Nov 2020818040
Dec 202010810839
Jan 202112512550
Feb 202110710735
Mar 202117717740
Apr 202114714751
May 202116116147
Jun 202113813842
Jul 202118818874
Aug 202111711755
Sep 202111511555
Oct 202114014053
Nov 202113313655
Dec 202110510641
Jan 202215315747
Feb 202211011335
Mar 202216016888
Apr 202219620366
May 202211812847
Jun 202212813150
Jul 2022929938
Aug 2022859040
Sep 2022969748
Oct 2022869228
Nov 2022939554
Dec 2022666616
Jan 2023666618
Feb 202311711735
Mar 2023959631
Apr 2023767724
May 2023919125
Jun 202311311736
Jul 2023747424
Aug 2023616119
Sep 2023686818
Oct 2023757915
Nov 2023909118
Dec 2023757516
Jan 2024747510
Feb 2024808030
Mar 202410610670
Apr 2024696932
May 2024767735
Jun 2024818332
Jul 2024747532
Aug 2024747524
Sep 2024545428
Oct 2024919140
Nov 2024939634
Dec 202413213559
Jan 2025636424
Feb 202514914939
Mar 2025757631
Apr 2025939436
May 2025858531
Jun 2025616320
Jul 2025110
May 2026220
Total638364682395